import{_ as l,c as i,o as t,ag as g}from"./chunks/framework.Bw-5EFTY.js";const B="data:image/png;base64,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",E="data:image/png;base64,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",Q="data:image/png;base64,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",d="data:image/png;base64,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",S=JSON.parse('{"title":"藥物疹","description":"","frontmatter":{"title":"藥物疹","updated":"2025-05-29T23:57:46.000Z","created":"2025-02-16T11:19:19.000Z"},"headers":[],"relativePath":"other-specialties/皮膚科/藥物疹.md","filePath":"other-specialties/皮膚科/藥物疹.md"}'),C={name:"other-specialties/皮膚科/藥物疹.md"};function r(I,A,e,s,o,u){return t(),i("div",null,A[0]||(A[0]=[g('<p>藥物疹 2025年2月16日 上午 11:19</p><table><colgroup><col style="width:46%;"><col style="width:22%;"><col style="width:21%;"><col style="width:9%;"></colgroup><thead><tr class="header"><th>臨床表現</th><th>由藥物引發的可能性</th><th>發作起始時間</th><th>致死率</th></tr></thead><tbody><tr class="odd"><td>固定性藥物疹(Fixed drug eruption)</td><td>100%</td><td><p>初次：1–2 週</p><p>再次暴露：&lt;48小時</p><p>(大多在24小時以內)</p></td><td>0%</td></tr><tr class="even"><td><p>Drug reaction with eosinophilia and</p><p>systemic symptoms (DRESS)/drug-induced</p><p>hypersensitivity syndrome (DIHS)</p></td><td>70-90%</td><td>15-40天</td><td>5-10%</td></tr><tr class="odd"><td><p>Stevens–Johnson syndrome</p><p>Toxic epidermal necrolysis</p></td><td>70-90%</td><td>7-21天</td><td><p>5%</p><p>30%</p></td></tr></tbody></table> | 特徵 | DRESS | SJS/TEN | AGEP | |----|----|----|----| | 發病時間 | 延遲 (2-8 週) | 早期 (7-21 天) | 非常迅速 (\\&lt;4 天) | | 皮膚特徵 | 麻疹樣變水腫、臉部水腫、可能多形性紅疹 | 暗紅斑塊伴表皮剝離，邊緣不清的靶心樣病灶 | 許多無菌性膿疱，紅斑水腫基底 | | 黏膜受累 | 通常輕微或無 | 嚴重 ( \\&gt;90% 病例) | 約 50% 病例 | | 全身性受累 | 顯著，多器官受累常見 (肝、腎、肺等)2... | 通常有發燒等，但主要問題是表皮剝離21... | 少見 (~17%) | | 實驗室異常 | **嗜酸性球增多**，非典型淋巴細胞增多，肝臟酵素升高 | 血球低下 (淋巴球、嗜中性球、血小板) | **嗜中性球增多**、輕度嗜酸球增多 | | 組織病理 | 變異大，常有嗜酸性球浸潤，無廣泛表皮壞死 | **廣泛角質細胞壞死**，表皮剝離，真皮發炎細胞稀少 | **角質層下膿疱**，真皮血管周圍嗜中性球浸潤 | | 常見病因 | 藥物 (抗癲癇藥、抗生素) | 藥物 | 藥物 | | 病毒關聯 | 常伴 HHV-6 等再活化 | 可能與 *Mycoplasma pneumoniae* 或病毒有關，但不如藥物重要 | 少見，可能有病毒感染誘發 | | 預後 | 潛在致命 (2-10%) | 高致死率 (SJS 5%、TEN 15-35%) | 低致死率 (1-2%)、自限性 | <ul><li><p>名詞定義：</p><ul><li>嚴重皮膚不良反應(Severe cutaneous adverse reactions, SCARs) <ul><li>Anaphylaxis</li><li>Anticoagulant-induced skin necrosis</li><li>Acute generalized exanthematous pustulosis (AGEP)</li><li>Drug rash with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS)</li><li>Generalized bullous fixed drug eruption</li><li>Stevens–Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN)</li></ul></li></ul></li><li><p>固定性藥物疹(Fixed drug eruption)</p><ul><li>定義： <ul><li>初次接觸：初次接觸特定藥物引發固定性藥物疹時，病灶通常會在給藥後幾天到兩週內 (1-2 週)出現</li><li>再次接觸：再次接觸同種藥物時，病灶會在完全相同的部位快速復發 <ul><li>復發的發生速度會非常快(&lt;48 小時，通常在 24 小時內)</li></ul></li></ul></li><li>病因： <ul><li>過敏引起的皮膚血管炎反應</li><li>常見引起藥物診藥物： <ul><li>抗生素： <ul><li>Sulfa類(最常見)、Tetracyclines &gt; β-lactams、fluoroquinolones、macrolides</li></ul></li><li>止痛退燒藥： <ul><li>NSAIDs、acetaminophen、aspirin</li></ul></li><li>其他藥物： <ul><li>Barbiturates、Dapsone、PPI、Azole類抗黴菌藥物、Pseudoephedrine</li></ul></li></ul></li></ul></li><li>病生理：Type 4過敏反應 <img src="'+B+'" alt="image1"></li></ul></li><li><p>臨床表現：</p><ul><li>發病時間： <ul><li>初次接觸： 1-2 週後出現</li><li>再次接觸：&lt;48 小時，通常在 24 小時內</li></ul></li><li>常見部位：生殖器、肛門周圍 、手腳、臉部、嘴唇</li><li>發作型態： <ul><li>邊界清晰、卵圓形紅斑塊(通常為單一)伴隨著搔癢及發熱症狀→水腫狀斑塊→脫屑(desquamation)並產生色素沈著(棕色、黑色斑) <ul><li>可能有標靶病變(target lesion)</li></ul></li><li>每次服用相同藥物後，都會在相同部位出現藥物疹的現象</li></ul></li></ul></li><li><p>診斷：</p><ul><li>主要基於病史(包括用藥史和病灶復發的特徵)、臨床表現</li><li>皮膚激發(provocation test)試驗 <ul><li>建議在過敏發作結束後一段時間內(4-6週)進行，以免受耐受期(refractory period)影響</li><li>協助釐清致病藥物</li><li>試驗種類： <ul><li>oral challenge test <ul><li>病人暴露於懷疑藥物中，增加劑量直到給予完整劑量或發生過敏反應為止</li><li>測試過程中能耐受藥物並完成完整劑量，則表示病人對該藥物沒有藥物過敏反應</li></ul></li><li>skin patch test(陽性率&gt;40%) <ul><li>貼於上背部並保留48小時</li><li>在 3-7 天時進行判讀</li><li>建議在曾有病灶的部位進行原位貼膚試驗 (in situ patch test)</li></ul></li></ul></li></ul></li></ul></li><li><p>處置：</p><ul><li><strong>立即停用懷疑致病藥物</strong></li></ul></li><li><p>預後：</p><ul><li>通常是自限性疾病，通常在停藥後幾天內消退(可能需1-2週才能完全消退)</li><li>再次用藥時可能復發</li></ul></li><li><p>Stevens-Johnson syndrome(SJS)、毒性表皮壞死溶解症(Toxic epidermal necrolysis, TEN)</p><ul><li>定義：依水泡、破皮面積佔全身體表面積(body surface area, BSA)比例 <ul><li>SJS：&lt;10% BSA</li><li>SJS-TEN overlap：10-30% BSA</li><li>TEN：&gt;30% BSA</li></ul></li><li>流行病學： <ul><li>女 &gt; 男(1.5：1)</li><li>發病年齡：任何年齡都可能發生</li></ul></li><li>病因：幾乎是藥物造成、感染/疫苗相對罕見 <ul><li>常見藥物：抗癲癇藥物(carbamazepine、phenytoin、Lamotrigine)、allopurinol、sulfa類抗生素、NSAID</li><li>亞洲種族：HLA-B基因型與特定藥物所引起的SJS/TEN相關 <ul><li>HLA-B*1502(carbamazepine、phenytoin、Lamotrigine)</li><li>HLA-B*5801(allopurinol) <img src="'+E+'" alt="image2"></li></ul></li></ul></li></ul></li></ul><p>(參考資料)Dermatology 4th ed. p.349</p><ul><li>病生理： <ul><li>目前認為和藥物激發Type 4過敏反應有關 <ul><li>透過與人類白血球抗原(HLA)的交互作用活化特異CD8+T cell→T cell增生、浸潤到皮膚組織中攻擊表皮細胞→表皮細胞大量的凋亡(apoptosis)</li><li>皮膚切片中會看到<strong>整層表皮的壞死與溶解</strong></li></ul></li></ul></li><li>臨床表現： <ul><li>前驅症狀：被觸發後1-3週 <ul><li>發燒、喉嚨痛</li><li>肌痛、關節痛</li><li>頭痛</li><li>結膜發紅、嘴巴破皮、生殖泌尿道等黏膜破皮</li></ul></li><li>皮膚黏膜病變：前驅症狀出現後1-3天 <ul><li>皮膚病變：影響所有患者 <ul><li>臉部和軀幹最初出現疼痛性紅斑，中心呈紫斑狀(非典型target lesion)</li><li>快速擴散並融合成大水泡(bullae)，擴展至廣泛表皮壞死、真皮/表皮分離與表皮脫落</li><li>表皮脫落後1-2週再上皮化(Reepithelialization)</li><li><strong>Nikolsky sign(+)</strong></li></ul></li><li>黏膜病變： ≧ 90%患者 <ul><li>口腔：口腔炎、唇炎、潰瘍</li><li>眼部：結膜炎、角膜炎、虹膜炎、前葡萄膜炎</li><li>生殖泌尿道：生殖器糜爛(如龜頭糜爛、外陰糜爛、陰道糜爛)、尿道糜爛</li></ul></li></ul></li></ul></li><li>診斷： <ul><li>臨床診斷：根據病史、黏膜皮膚病變診斷</li><li>確認診斷：皮膚切片(裂解位置：Stratum germinativum) <img src="'+Q+'" alt="image3"></li></ul></li><li>併發症： <ul><li>大面積皮膚脫落，剩下真皮層裸露在外 <ul><li>急性：脫水、體溫/電解質失調、低血容性休克、繼發性感染、敗血症和感染性休克</li><li>眼科：眼部疤痕和視力喪失(最常見)、乾性角結膜炎、睫毛倒刺(Trichiasis)</li><li>皮膚科：色素沉澱、色素沉澱過少、掉髮、指甲脫落</li><li>泌尿生殖系統：尿道狹窄、陰道沾黏、性交困難、包莖、性功能障礙</li><li>胃腸道：狹窄、緊縮、吞嚥困難</li></ul></li></ul></li><li>處置： <ul><li><strong>立即停用懷疑致病藥物</strong></li><li>支持性療法：與大面積燒傷類似，維持生理穩定、預防併發症發生 <ul><li>傷囗、黏膜照護 <ul><li>非脫皮區域保持乾燥</li><li>臉部：結痂以生理食鹽水每日清洗，必要時使用抗生素藥膏</li><li>眼睛：每日眼科評估，生理食鹽水清洗 + 抗生素眼膏與眼藥水</li><li>口腔：定時以生理食鹽水沖洗，昏迷者需抽吸避免吸入性肺炎</li><li>鼻腔、耳朵：棉棒清潔 + 抗生素或凡士林藥膏</li><li>肛門生殖區、指間：每日清潔，潮濕導致浸潤(maceration)者可用0.5%硝酸銀溶液</li></ul></li><li>維持電解質及體液平衡</li><li>適當鎮靜止痛</li><li>良好呼吸照護</li></ul></li><li>系統性治療 <ul><li><strong>類固醇</strong></li><li><strong>免疫抑制劑</strong></li><li><strong>IVIG、血漿交換術</strong>：移除血中免疫活性物質、降低過敏反應</li></ul></li></ul></li><li>預後： <ul><li>SJS平均死亡率：1-5%</li><li>TEN平均死亡率：25-35%</li><li>預後評估：Severity-of-Illness Score for Toxic Epidermal Necrolysis (SCORTEN) <img src="'+d+'" alt="image4"></li></ul></li><li>Drug reaction with eosinophilia and systemic symptoms (DRESS) = Drug-induced hypersensitivity syndrome (DIHS) <ul><li>定義： <ul><li>罕見、潛在致命的免疫介導性藥物不良反應，特徵是皮膚表現伴隨內部器官影響</li></ul></li><li>病因： <ul><li>幾乎由藥物引起(70-90%) <ul><li>抗癲癇藥：lamotrigine、phenytoin、carbamazepine、phenobarbital、oxcarbazepine、zonisamide</li><li>抗生素：dapsone、sulfamethoxazole/trimethoprim、piperacillin/tazobactam、vancomycin、minocycline、abacavir、nevirapine、磺胺類藥物、rifampicin</li><li>Allopurinol</li></ul></li><li>HHV-6初次感染或再次活化</li></ul></li><li>危險因子：免疫低下族群、藥物基因易感性(Pharmacogenetic susceptibility)</li><li>病生理學： <ul><li>遺傳易感性與Type 4過敏反應之間的相互作用</li><li>與IL-5活化嗜酸性細胞增生、皮膚和內臟器官中藥物特異性 T cell活化有關</li></ul></li><li>臨床表現： <ul><li>發病時間 (Time interval) <ul><li>初次接觸：通常在藥物暴露後 2-8 週出現症狀</li><li>再次接觸：暴露後數小時或數天</li></ul></li><li>症狀： <ul><li>發燒(通常是高燒，&gt;38.5°C，伴隨高低起伏)(85%)</li><li>瀰漫性皮疹(75%)：以麻疹樣皮疹開始，隨後變為水腫樣</li><li>淋巴結腫大</li><li>臉部水腫</li><li>內部器官影響(見&quot;併發症&quot;)</li></ul></li></ul></li><li>診斷： <ul><li>主要基於臨床表現(發燒、瀰漫性皮疹)、詳細的藥物史(最近 2-8 週內開始使用的藥物)、是否有內部器官受影響、是否有嗜酸性球增加(常見)綜合判斷</li><li>RegiSCAR score：協助診斷DRESS</li></ul></li></ul></li></ul><table style="width:100%;"><colgroup><col style="width:47%;"><col style="width:10%;"><col style="width:9%;"><col style="width:16%;"><col style="width:16%;"></colgroup><thead><tr class="header"><th><strong>項目</strong></th><th><strong>Yes</strong></th><th><strong>No</strong></th><th><strong>Unknown</strong></th><th><strong>說明</strong></th></tr></thead><tbody><tr class="odd"><td><strong>發燒 &gt;38.5°C</strong></td><td>0</td><td>-1</td><td>-1</td><td>必要項目之一</td></tr><tr class="even"><td><strong>淋巴結腫大（≥2處，且每處&gt;1 cm）</strong></td><td>1</td><td>0</td><td>0</td><td>典型表現</td></tr><tr class="odd"><td><strong>非典型淋巴球（Atypical lymphocytes）</strong></td><td>1</td><td>0</td><td>0</td><td></td></tr><tr class="even"><td><strong>嗜酸性球</strong></td><td></td><td></td><td></td><td>以下擇一計分</td></tr><tr class="odd"><td>700–1499 或佔白血球10–19.9%</td><td>1</td><td>0</td><td>0</td><td></td></tr><tr class="even"><td>≥1500 或 ≥20%</td><td>2</td><td>0</td><td>0</td><td></td></tr><tr class="odd"><td><strong>皮疹</strong></td><td></td><td></td><td></td><td>以下三項獨立計分</td></tr><tr class="even"><td>面積 &gt;50% 體表面積</td><td>1</td><td>0</td><td>0</td><td></td></tr><tr class="odd"><td>具2種以上特徵(如水腫、浸潤、紫癜、脫屑)</td><td>1</td><td>-1</td><td>0</td><td></td></tr><tr class="even"><td>皮膚切片符合 DRESS</td><td>0</td><td>-1</td><td>0</td><td></td></tr><tr class="odd"><td><strong>器官影響</strong></td><td></td><td></td><td></td><td>以下擇一計分</td></tr><tr class="even"><td>一個器官</td><td>1</td><td>0</td><td>0</td><td></td></tr><tr class="odd"><td>兩個以上器官</td><td>2</td><td>0</td><td>0</td><td></td></tr><tr class="even"><td><strong>症狀持續超過15天</strong></td><td>0</td><td>-1</td><td>-1</td><td></td></tr><tr class="odd"><td><strong>已排除其他診斷(完成至少3項生化檢查且為陰性)</strong></td><td>1</td><td>0</td><td>0</td><td></td></tr><tr class="even"><td><strong>總分與診斷標準</strong></td><td></td><td></td><td></td><td></td></tr><tr class="odd"><td><p><strong>≤1否定(No case)</strong></p><p><strong>2–3可能(Possible case)</strong></p><p><strong>4–5可能性高(Probable case)</strong></p><p><strong>≥6確診(Definite case)</strong></p></td><td></td><td></td><td></td><td></td></tr></tbody></table><ul><li>處置： <ul><li><strong>立即停用懷疑致病藥物</strong></li><li><strong>全身性類固醇</strong>(PO、IV)：1st line，通常需要長時間的逐漸減量</li><li>其他治療：<strong>cyclosporine、cyclophosphamide、血漿置換術、IVIg</strong><ul><li>通常用於難治性病例或對皮質類固醇有禁忌症時</li></ul></li></ul></li><li>併發症： <ul><li>其他器官侵犯：常見影響器官包括肝臟(最常見)、腎臟、肺部、心臟、肌肉、胰臟 <ul><li>肝臟：肝臟壞死、衰竭</li><li>腎臟：GFR↓、急性間質腎炎</li><li>心臟：心肌炎</li><li>肌肉：肌肉痠痛、無力</li><li>胰臟：amylase/lipase↑、胰臟炎</li></ul></li><li>多重器官衰竭</li></ul></li><li>預後： <ul><li>死亡率約2-10%</li><li>肝臟壞死導致肝臟衰竭為主要死因</li><li>延遲停藥會使預後惡化</li><li>症狀可能需要數週或數月才能緩解</li></ul></li><li>急性廣泛性發疹性膿疱病 (Acute Generalized Exanthematous Pustulosis, AGEP) <ul><li>流行病學： <ul><li>HLA-B5、-DR11、-DQ3 在 AGEP 患者中更常見</li></ul></li><li>病因：最常見的原因是藥物(超過90%病例) <ul><li>常見藥物： <ul><li>抗生素：Penicillins、Cephalosporins、Clindamycin、磺胺類藥物、Metronidazole、Carbapenems、Quinolones、Macrolides</li><li>鈣離子通道阻滯劑 (Calcium channel blockers)：特別是Diltiazem</li></ul></li><li>其他罕見原因包括： <ul><li>病毒感染(如腸病毒)</li><li>汞</li><li>疫苗</li><li>胰島素注射(罕見)</li></ul></li></ul></li><li>病生理學：Type 4過敏反應</li><li>臨床表現： <ul><li>發病：非常迅速，通常在給藥後短於 4 天出現皮疹。再次接觸致病藥物時，發病時間會更短</li><li>皮膚病灶： <ul><li>皮疹通常開始於臉部或主要的皺摺區(如腋窩和腹股溝)，然後在數小時內擴散全身，通常持續 1-2 週 <ul><li>特徵為大量、微小 (&lt;5 mm)、主要為非毛囊性、無菌性膿疱</li><li>發生在全身的水腫性紅斑皮膚上，膿疱可能匯合</li><li>消退後通常會出現表面脫屑</li></ul></li><li>可能伴隨灼熱感、瘙癢</li></ul></li><li>黏膜侵犯(50%)</li><li>全身症狀： <ul><li>常伴隨高燒 (通常 ≥ 38.5°C)</li><li>少數患者(17%)有全身系統侵犯 <ul><li>主要部位是肝臟、腎臟和肺部(急性呼吸窘迫)</li><li>其他特徵： <ul><li>白血球升高伴明顯嗜中性球增多、輕度至中度嗜酸性粒細胞增多</li><li>短暫腎功能不全</li><li>肝功能異常</li><li>低血鈣</li></ul></li></ul></li></ul></li></ul></li><li>處置： <ul><li>立即停用所有可能的致病藥物</li><li>支持性治療</li><li>通常不常規推薦預防性抗生素，除非有感染跡象</li></ul></li><li>預後： <ul><li>通常是自限性疾病</li><li>皮疹通常在停藥後 1-2 週內消退</li><li>不會進展為毒性表皮壞死症 (TEN)</li><li>死亡率相對較低(約1-2%)</li></ul></li></ul></li></ul>',8)]))}const a=l(C,[["render",r]]);export{S as __pageData,a as default};
